Future landscape of hepatitis C research – Basic, translational and clinical perspectives

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages S143-S155

  Moradpour, Darius ^a   Grakoui, Arash ^b   Manns, Michael P ^c,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Direct acting antivirals; Life cycle; Liver; Viral hepatitis

Indexed keywords

HEPACIVIRIN INHIBITOR; INTERFERON; NONSTRUCTURAL PROTEIN 5A INHIBITOR; VIRUS RNA; VIRUS VACCINE; ANTIVIRUS AGENT; HEPATITIS VACCINE;

BASIC RESEARCH; CELL STRUCTURE; CLINICAL PRACTICE; CYTOLOGY; DECOMPENSATED LIVER CIRRHOSIS; HEALTH CARE ACCESS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS E; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RNA REPLICATION; SCREENING; TAXONOMY; TRANSLATIONAL RESEARCH; TREATMENT DURATION; VACCINATION; VIRAL CLEARANCE; VIRUS ENTRY; VIRUS HEPATITIS; VIRUS RELEASE; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS C; COMPLICATION; DRUG DEVELOPMENT; GENETICS; GENOTYPE; HEALTH CARE DELIVERY; HEPACIVIRUS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; LIVER TUMOR; PHYSIOLOGY; SUSTAINED VIROLOGIC RESPONSE; TRENDS; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RENAL INSUFFICIENCY; SUSTAINED VIROLOGIC RESPONSE; TRANSLATIONAL MEDICAL RESEARCH; VIRAL HEPATITIS VACCINES;

EID: 85013447175     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.026     Document Type: Review

References (151)

1. [1] Bartenschlager, R., Lohmann, V., Penin, F., The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 11 (2013), 482–496.
2. [2] Manns, M.P., von Hahn, T., Novel therapies for hepatitis C – one pill fits all?. Nat Rev Drug Discovery 12 (2013), 595–610.
3. [3] Pawlotsky, J.M., Feld, J.J., Zeuzem, S., Hoofnagle, J.H., From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62 (2015), S87–S99.
4. [4] Scheel, T.K., Rice, C.M., Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19 (2013), 837–849.
5. [5] Poulot A and Penin F. The HCV life cycle. Available from: http://hcvlifecycle.univ-lyon1.fr.
6. [6] Moradpour, D., Penin, F., Rice, C.M., Replication of hepatitis C virus. Nat Rev Microbiol 5 (2007), 453–463.
7. [7] Bartenschlager R, editor. Hepatitis C virus: from molecular virology to antiviral therapy. Curr Top Microbiol Immunol. Springer; 2013.
8. [8] Haug, C.J., Kieny, M.P., Murgue, B., The Zika Challenge. N Engl J Med 374 (2016), 1801–1803.
9. [9] Lindenbach, B.D., What's next for hepatitis C virus research?. Hepatology 63 (2016), 1408–1410.
10. [10] Firth, C., Bhat, M., Firth, M.A., Williams, S.H., Frye, M.J., Simmonds, P., et al. Detection of zoonotic pathogens and characterization of novel viruses carried by commensal Rattus norvegicus in New York City. MBio 5 (2014), e01933–e01944.
11. [11] Scheel, T.K., Simmonds, P., Kapoor, A., Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses. Antiviral Res 115 (2015), 83–93.
12. [12] Corman, V.M., Grundhoff, A., Baechlein, C., Fischer, N., Gmyl, A., Wollny, R., et al. Highly divergent hepaciviruses from African cattle. J Virol 89 (2015), 5876–5882.
13. [13] Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., Bartenschlager, R., Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999), 110–113.
14. [14] Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005), 791–796.
15. [15] Billerbeck, E., de Jong, Y., Dorner, M., de la Fuente, C., Ploss, A., Animal models for hepatitis C. Curr Top Microbiol Immunol 369 (2013), 49–86.
16. [16] Steinmann, E., Pietschmann, T., Cell culture systems for hepatitis C virus. Curr Top Microbiol Immunol 369 (2013), 17–48.
17. [17] Yamane, D., McGivern, D.R., Wauthier, E., Yi, M., Madden, V.J., Welsch, C., et al. Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20 (2014), 927–935.
18. [18] Saeed, M., Andreo, U., Chung, H.Y., Espiritu, C., Branch, A.D., Silva, J.M., et al. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524 (2015), 471–475.
19. [19] Bartenschlager, R., Penin, F., Lohmann, V., Andre, P., Assembly of infectious hepatitis C virus particles. Trends Microbiol 19 (2011), 95–103.
20. [20] Lindenbach, B.D., Rice, C.M., The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11 (2013), 688–700.
21. [21] Catanese, M.T., Uryu, K., Kopp, M., Edwards, T.J., Andrus, L., Rice, W.J., et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A 110 (2013), 9505–9510.
22. [22] Merz, A., Long, G., Hiet, M.S., Brugger, B., Chlanda, P., Andre, P., et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286 (2011), 3018–3032.
23. [23] Lussignol, M., Kopp, M., Molloy, K., Vizcay-Barrena, G., Fleck, R.A., Dorner, M., et al. Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis. Proc Natl Acad Sci U S A 113 (2016), 2484–2489.
24. [24] Dorner, M., Horwitz, J.A., Donovan, B.M., Labitt, R.N., Budell, W.C., Friling, T., et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501 (2013), 237–241.
25. [25] de Jong, Y.P., Dorner, M., Mommersteeg, M.C., Xiao, J.W., Balazs, A.B., Robbins, J.B., et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med, 6(254), 2014, 254ra129.
26. [26] Mailly, L., Xiao, F., Lupberger, J., Wilson, G.K., Aubert, P., Duong, F.H., et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 33 (2015), 549–554.
27. [27] Zona, L., Lupberger, J., Sidahmed-Adrar, N., Thumann, C., Harris, H.J., Barnes, A., et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13 (2013), 302–313.
28. [28] Gerold, G., Meissner, F., Bruening, J., Welsch, K., Perin, P.M., Baumert, T.F., et al. Quantitative proteomics identifies serum response factor binding protein 1 as a host factor for hepatitis C virus entry. Cell Rep 12 (2015), 864–878.
29. [29] Ujino, S., Nishitsuji, H., Hishiki, T., Sugiyama, K., Takaku, H., Shimotohno, K., Hepatitis C virus utilizes VLDLR as a novel entry pathway. Proc Natl Acad Sci U S A 113 (2016), 188–193.
30. [30] Kolykhalov, A.A., Agapov, E.V., Blight, K.J., Mihalik, K., Feinstone, S.M., Rice, C.M., Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277 (1997), 570–574.
31. [31] Fraser, C.S., Doudna, J.A., Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol 5 (2007), 29–38.
32. [32] Niepmann, M., Hepatitis C virus RNA translation. Curr Top Microbiol Immunol 369 (2013), 143–166.
33. [33] You, S., Stump, D.D., Branch, A.D., Rice, C.M., A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 78 (2004), 1352–1366.
34. [34] Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M., Sarnow, P., Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309 (2005), 1577–1581.
35. [35] Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327 (2010), 198–201.
36. [36] Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 368 (2013), 1685–1694.
37. [37] Pirakitikulr, N., Kohlway, A., Lindenbach, B.D., Pyle, A.M., The coding region of the HCV genome contains a network of regulatory RNA structures. Mol Cell 62 (2016), 111–120.
38. [38] Li, Y., Yamane, D., Masaki, T., Lemon, S.M., The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. Nat Rev Microbiol 13 (2015), 544–558.
39. [39] Luna, J.M., Scheel, T.K., Danino, T., Shaw, K.S., Mele, A., Fak, J.J., et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 160 (2015), 1099–1110.
40. [40] Moradpour, D., Penin, F., Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 369 (2013), 113–142.
41. [41] Kong, L., Giang, E., Nieusma, T., Kadam, R.U., Cogburn, K.E., Hua, Y., et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342 (2013), 1090–1094.
42. [42] El Omari, K., Iourin, O., Kadlec, J., Sutton, G., Harlos, K., Grimes, J.M., et al. Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1. Nat Commun, 5, 2014, 4874.
43. [43] Khan, A.G., Whidby, J., Miller, M.T., Scarborough, H., Zatorski, A.V., Cygan, A., et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509 (2014), 381–384.
44. [44] Khan, A.G., Miller, M.T., Marcotrigiano, J., HCV glycoprotein structures: what to expect from the unexpected. Curr Opin Virol 12 (2015), 53–58.
45. [45] Gouttenoire, J., Penin, F., Moradpour, D., Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev Med Virol 20 (2010), 117–129.
46. [46] Reiss, S., Harak, C., Romero-Brey, I., Radujkovic, D., Klein, R., Ruggieri, A., et al. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog, 9, 2013, e1003359.
47. [47] Kazakov, T., Yang, F., Ramanathan, H.N., Kohlway, A., Diamond, M.S., Lindenbach, B.D., Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins. PLoS Pathog, 11, 2015, e1004817.
48. [48] Romero-Brey, I., Berger, C., Kallis, S., Kolovou, A., Paul, D., Lohmann, V., et al. NS5A domain 1 and polyprotein cleavage kinetics are critical for induction of double-membrane vesicles associated with hepatitis C virus replication. MBio, 6, 2015, e00759.
49. [49] Shulla, A., Randall, G., Spatiotemporal analysis of hepatitis C virus infection. PLoS Pathog, 11, 2015, e1004758.
50. [50] Lohmann, V., Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 369 (2013), 167–198.
51. [51] Paul, D., Madan, V., Bartenschlager, R., Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 16 (2014), 569–579.
52. [52] Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465 (2010), 96–100.
53. [53] Ascher, D.B., Wielens, J., Nero, T.L., Doughty, L., Morton, C.J., Parker, M.W., Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep, 4, 2014, 4765.
54. [54] Berger, C., Romero-Brey, I., Radujkovic, D., Terreux, R., Zayas, M., Paul, D., et al. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology 147 (2014), 1094–1095, e25.
55. [55] McGivern, D.R., Masaki, T., Williford, S., Ingravallo, P., Feng, Z., Lahser, F., et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147 (2014), 453–462, e7.
56. [56] Nettles, J.H., Stanton, R.A., Broyde, J., Amblard, F., Zhang, H., Zhou, L., et al. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. J Med Chem 57 (2014), 10031–10043.
57. [57] Barakat, K.H., Anwar-Mohamed, A., Tuszynski, J.A., Robins, M.J., Tyrrell, D.L., Houghton, M., A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J Chem Inf Model 55 (2015), 362–373.
58. [58] Sun, J.H., O'Boyle, D.R. 2nd, Fridell, R.A., Langley, D.R., Wang, C., Roberts, S.B., et al. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. Nature 527 (2015), 245–248.
59. [59] Feng, Z., Hensley, L., McKnight, K.L., Hu, F., Madden, V., Ping, L., et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496 (2013), 367–371.
60. [60] Feng, Z., Hirai-Yuki, A., McKnight, K.L., Lemon, S.M., Naked viruses that aren't always naked: quasi-enveloped agents of acute hepatitis. Annu Rev Virol 1 (2014), 539–560.
61. [61] Walker, C.M., Feng, Z., Lemon, S.M., Reassessing immune control of hepatitis A virus. Curr Opin Virol 11 (2015), 7–13.
62. [62] Dalton, H.R., Webb, G.W., Norton, B.C., Woolson, K.L., Hepatitis E virus: time to change the textbooks. Dig Dis 34 (2016), 308–316.
63. [63] Debing, Y., Moradpour, D., Neyts, J., Gouttenoire, J., Update on hepatitis E virology: implications for clinical practice. J Hepatol 65 (2016), 200–212.
64. [64] Zeisel, M.B., Lucifora, J., Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure. Gut 64 (2015), 1314–1326.
65. [65] Liang, T.J., Block, T.M., McMahon, B.J., Ghany, M.G., Urban, S., Guo, J.T., et al. Present and future therapies of hepatitis B: From discovery to cure. Hepatology 62 (2015), 1893–1908.
66. [66] Revill, P., Testoni, B., Locarnini, S., Zoulim, F., Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol 13 (2016), 239–248.
67. [67] Dahari, H., Feinstone, S.M., Major, M.E., Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 139 (2010), 965–974.
68. [68] Sacks-Davis, R., Grebely, J., Dore, G.J., Osburn, W., Cox, A.L., Rice, T.M., et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection–the InC3 study. J Infect Dis 212 (2015), 1407–1419.
69. [69] Gerlach, J.T., Diepolder, H.M., Jung, M.C., Gruener, N.H., Schraut, W.W., Zachoval, R., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 (1999), 933–941.
70. [70] Ulsenheimer, A., Lucas, M., Seth, N.P., Tilman Gerlach, J., Gruener, N.H., Loughry, A., et al. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat 13 (2006), 708–714.
71. [71] Neumann-Haefelin, C., Thimme, R., Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol 369 (2013), 243–262.
72. [72] Schulze Zur Wiesch, J., Ciuffreda, D., Lewis-Ximenez, L., Kasprowicz, V., Nolan, B.E., Streeck, H., et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 209 (2012), 61–75.
73. [73] Day, C.L., Seth, N.P., Lucas, M., Appel, H., Gauthier, L., Lauer, G.M., et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 112 (2003), 831–842.
74. [74] zur Wiesch, J. Schulze, Lauer, G.M., Day, C.L., Kim, A.Y., Ouchi, K., Duncan, J.E., et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175 (2005), 3603–3613.
75. [75] Cabrera, R., Tu, Z., Xu, Y., Firpi, R.J., Rosen, H.R., Liu, C., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 (2004), 1062–1071.
76. [76] Sugimoto, K., Ikeda, F., Stadanlick, J., Nunes, F.A., Alter, H.J., Chang, K.M., Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38 (2003), 1437–1448.
77. [77] Kared, H., Fabre, T., Bedard, N., Bruneau, J., Shoukry, N.H., Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog, 9, 2013, e1003422.
78. [78] Fuller, M.J., Shoukry, N.H., Gushima, T., Bowen, D.G., Callendret, B., Campbell, K.J., et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 51 (2010), 378–387.
79. [79] Crawford, A., Angelosanto, J.M., Kao, C., Doering, T.A., Odorizzi, P.M., Barnett, B.E., et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 40 (2014), 289–302.
80. [80] Diepolder, H.M., Zachoval, R., Hoffmann, R.M., Jung, M.C., Gerlach, T., Pape, G.R., The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med (Berl) 74 (1996), 583–588.
81. [81] Lucas, M., Ulsenheimer, A., Pfafferot, K., Heeg, M.H., Gaudieri, S., Gruner, N., et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One, 2, 2007, e649.
82. [82] Radziewicz, H., Ibegbu, C.C., Fernandez, M.L., Workowski, K.A., Obideen, K., Wehbi, M., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 81 (2007), 2545–2553.
83. [83] Kroy, D.C., Ciuffreda, D., Cooperrider, J.H., Tomlinson, M., Hauck, G.D., Aneja, J., et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146 (2014), 550–561.
84. [84] Park, S.H., Rehermann, B., Immune responses to HCV and other hepatitis viruses. Immunity 40 (2014), 13–24.
85. [85] Grakoui, A., Shoukry, N.H., Woollard, D.J., Han, J.H., Hanson, H.L., Ghrayeb, J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003), 659–662.
86. [86] Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J.A., Castelblanco, N., Rosen, H.R., Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81 (2007), 9249–9258.
87. [87] Urbani, S., Amadei, B., Tola, D., Massari, M., Schivazappa, S., Missale, G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80 (2006), 11398–11403.
88. [88] Fuller, M.J., Callendret, B., Zhu, B., Freeman, G.J., Hasselschwert, D.L., Satterfield, W., et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A 110 (2013), 15001–15006.
89. [89] McMahan, R.H., Golden-Mason, L., Nishimura, M.I., McMahon, B.J., Kemper, M., Allen, T.M., et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120 (2010), 4546–4557.
90. [90] Youngblood, B., Oestreich, K.J., Ha, S.J., Duraiswamy, J., Akondy, R.S., West, E.E., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35 (2011), 400–412.
91. [91] Manns, M., Pol, S., Jacobson, I.M., Marcellin, P., Gordon, S.C., Peng, C.Y., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384 (2014), 1597–1605.
92. [92] Chu C, et al. Poster P006 (M13–767). APASL STC 2016; 2016; Taiwan.
93. [93] Chu C, et al. Poster P007 (M14–491). APASL STC 2016; 2016; Taiwan.
94. [94] Wyles, D.L., Ruane, P., Sulkowski, M.S., Dieterich, D., Luetkemeyer, A.F., Morgan, T.R., et al. Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1–4 in Hiv-Hcv coinfection: the ally-2 study. J Hepatol, 62, 2015, S263-S.
95. [95] Pawlotsky, J.M., Hepatitis, C., Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151 (2016), 70–86.
96. [96] Lawitz, E., Flamm, S., Yang, J.C., Pang, P.S., Zhu, Y., Svarovskaia, E., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir- based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol, 62, 2015, S192-S.
97. [97] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
98. [98] Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
99. [99] Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
100. [100] Hezode, C.R.N., Svarovskaia, E.S., Doehle, B., Chodavarapu, K., Dvory-Sobol, H., McNally, J., et al. Resistance analysis in 1284 patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 studies. J Hepatol 64 (2016), S399–S400.
101. [101] Poordad, F., Bennett, M., Sepe, T.E., Cohen, E., Reindollar, R.W., Everson, G., et al. Ombitasvir/paritaprevir/R, dasabuvir and sofosbuvir treatment of patients with HCV genotype 1 infection who failed a prior course of DAA therapy: the QUARTZ-1 Study. J Hepatol 64 (2016), S767–S768.
102. [102] Poordad, F., Felizarta, F., Wang, S., Asatryan, A., Hassanein, T., Aguilar, H., et al. High SVR rates with the combination of ABT-493 + ABT-530 for 8 weeks in non-cirrhotic patients with HCV genotype 1 or 2 infection. J Hepatol, 64, 2016, S768.
103. [103] Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., et al. High efficacy of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1-6 HCV-infected patients, including those previously treated with direct-acting antivirals. J Hepatol 64 (2016), S139–S140.
104. [104] Tacke, F., Günther, R., Buggisch, P., Klinker, H., Schober, A., John, C., et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in low SVR rates in a real world cohort (German Hepatitis C Registry, DHC-R). J Hepatol, 64, 2016, S767.
105. [105] Susser, S., Dietz, J., Barak, M., Schlevogt, B., Daniel, R., Piazzolla, V., et al. Prevalence and clinical importance of hepatitis C virus genotype 2k/1b chimeras. J Hepatol, 64, 2016, S136.
106. [106] Pockros, P.J., Reddy, K.R., Mantry, P.S., Cohen, E., Bennett, M., Sulkowski, M.S., et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150 (2016), 1590–1598.
107. [107] Roth, D., Nelson, D.R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H. Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
108. [108] EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
109. [109] Chung, R.T., Davis, G.L., Jensen, D.M., Masur, H., Saag, M.S., Thomas, D.L., et al. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
110. [110] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
111. [111] Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
112. [112] Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004), 1521–1531.
113. [113] Papatheodoridis, G.V., Lampertico, P., Manolakopoulos, S., Lok, A., Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53 (2010), 348–356.
114. [114] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
115. [115] Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., Falck-Ytter, Y., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
116. [116] Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
117. [117] Kozbial, K., Stern, R., Freissmuth, C., Beinhardt, S., Stättermayer, A.F., Munda, P., et al. High risk for hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment within 1 year follow-up. J Hepatol 64 (2016), S617–S618.
118. [118] Pol, S., Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol 65 (2016), 734–740.
119. [119] Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
120. [120] Lok, A.S., Everhart, J.E., Wright, E.C., Di Bisceglie, A.M., Kim, H.Y., Sterling, R.K., et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140 (2011), 840–849 [Quiz e12].
121. [121] Bruix, J., Poynard, T., Colombo, M., Schiff, E., Burak, K., Heathcote, E.J., et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 140 (2011), 1990–1999.
122. [122] Hengst, J., Strunz, B., Deterding, K., Ljunggren, H.G., Leeansyah, E., Manns, M.P., et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol, 2016 in press.
123. [123] Meissner, E.G., Kohli, A., Virtaneva, K., Sturdevant, D., Martens, C., Porcella, S.F., et al. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat 23 (2016), 496–505.
124. [124] Gane, E.J., Hyland, R.H., Ying, Y., Svarovskaia, E., Stamm, L.M., Brainard, D.M., et al. Safety and efficacy of short-duration treatment with Gs-9857 combined with sofosbuvir/Gs-5816 in treatment-naive and Daa-experienced genotype 1 patients with and without cirrhosis. J Hepatol, 62, 2015, S264-S.
125. [125] Lawitz, E., Poordad, F., Gutierrez, J.A., Evans, B., Hwang, P., Robertson, M., et al. C-SWIFT: MK-5172+MK-8742+sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks. Hepatology 60 (2014), 1286A–1287A.
126. [126] Deterding, K., Spinner, C., Schott, E., Welzel, T., Gerken, G., Klinker, H., et al. Six weeks of sofosbuvir/ledipasvir are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET acute HCV IV study. J Hepatol, 64, 2016, S211.
127. [127] Lau, G.K., Benhamou, Y., Chen, G.F., Li, J., Shao, Q., Ji, D., et al. Complete cure after three weeks of all-oral triple-direct acting antiviral (DAA) regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI STUDY). Hepatology, 62, 2015, 1394A.
128. [128] Cornberg, M., Manns, M., Hepatitis C: individualised medicine versus one pill fits all. Lancet Gastroenterol Hepatol, 2016, 10.1016/S2468-1253(16)30029-2 in press.
129. [129] Razavi, H., Waked, I., Sarrazin, C., Myers, R.P., Idilman, R., Calinas, F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 (2014), 34–59.
130. [130] Midgard, H., Bjoro, B., Maeland, A., Konopski, Z., Kileng, H., Damas, J.K., et al. Hepatitis C reinfection after sustained virological response. J Hepatol 64 (2016), 1020–1026.
131. [131] Rockstroh J, Bhagani S, Hyland RH, Yun C, Zhang W, Brainard DM, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection. CROI 2016; Boston.
132. [132] Charlton, M., Gane, E., Manns, M.P., Brown, R.S., Curry, M.P., Kwo, P.Y., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
133. [133] Colombo, M.A.A., Liu, H., Dvory-Sobol, H., Hyland, R., Yun, C., Brainard, D.M., et al. Ledipasvir/sofosbuvir (LDV/SOF) for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection. J Hepatol, 64, 2016, S183.
134. [134] Negro, F., Forton, D., Craxi, A., Sulkowski, M.S., Feld, J.J., Manns, M.P., Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
135. [135] van der Meer, A.J., Wedemeyer, H., Feld, J.J., Dufour, J.F., Zeuzem, S., Hansen, B.E., et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
136. [136] Kawaguchi, T., Ide, T., Taniguchi, E., Hirano, E., Itou, M., Sumie, S., et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102 (2007), 570–576.
137. [137] Younossi, Z.M., Stepanova, M., Feld, J., Zeuzem, S., Jacobson, I., Agarwal, K., et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol 65 (2016), 33–39.
138. [138] Saadoun, D., Thibault, V., Si Ahmed, S.N., Alric, L., Mallet, M., Guillaud, C., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis, 2016 in press.
139. [139] Sise, M.E., Bloom, A.K., Wisocky, J., Lin, M.V., Gustafson, J.L., Lundquist, A.L., et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63 (2016), 408–417.
140. [140] Hermine, O., Lefrere, F., Bronowicki, J.P., Mariette, X., Jondeau, K., Eclache-Saudreau, V., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347 (2002), 89–94.
141. [141] La Mura, V., De Renzo, A., Perna, F., D'Agostino, D., Masarone, M., Romano, M., et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol 49 (2008), 557–563.
142. [142] Hagan, L.M., Wolpe, P.R., Schinazi, R.F., Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 21 (2013), 625–633.
143. [143] Kim, A.Y., Onofrey, S., Church, D.R., An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 207 (2013), S1–S6.
144. [144] Rehermann, B., Nascimbeni, M., Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 (2005), 215–229.
145. [145] Walker, C.M., Grakoui, A., Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?. Curr Opin Immunol 35 (2015), 137–143.
146. [146] Shoukry, N.H., Grakoui, A., Houghton, M., Chien, D.Y., Ghrayeb, J., Reimann, K.A., et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197 (2003), 1645–1655.
147. [147] Klenerman, P., Thimme, R., T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 61 (2012), 1226–1234.
148. [148] Osburn, W.O., Fisher, B.E., Dowd, K.A., Urban, G., Liu, L., Ray, S.C., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138 (2010), 315–324.
149. [149] Folgori, A., Capone, S., Ruggeri, L., Meola, A., Sporeno, E., Ercole, B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12 (2006), 190–197.
150. [150] Swadling, L., Capone, S., Antrobus, R.D., Brown, A., Richardson, R., Newell, E.W., et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med, 6, 2014, 261ra153.
151. [151] Scott, N., McBryde, E., Vickerman, P., Martin, N.K., Stone, J., Drummer, H., et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med, 13, 2015, 198.